一项比较不同剂量的 NN0519-0130 药物降低 2 型糖尿病患者血糖效果的研究
每周一次 NNC0519-0130 对 2 型糖尿病参与者的安全性和有效性调查 - 剂量探索研究
This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The study will test up to 7 different doses of NNC0519-0130. Which treatment participant will get is decided by chance. Participants will take 1-3 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 40 weeks.
研究概览
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
-
Québec、加拿大、G1V 4T3
- Diex Recherche Quebec
-
-
British Columbia
-
Kelowna、British Columbia、加拿大、V1Y 1Z9
- OCT Research ULC (dba Okanagan Clinical Trials)
-
Richmond、British Columbia、加拿大、V6V 2L1
- OCT Research ULC (dba Okanagan Clinical Trials)
-
Victoria、British Columbia、加拿大、V8V 4A1
- Cook Street Medical Clinic
-
-
New Brunswick
-
Moncton、New Brunswick、加拿大、E1G 1A7
- G.A. Research Associates Ltd.
-
-
Nova Scotia
-
Halifax、Nova Scotia、加拿大、B3H 1V7
- Nova Scotia Hlth Halifax
-
-
Ontario
-
Barrie、Ontario、加拿大、L4N 7L3
- Centricity Research Barrie
-
Hamilton、Ontario、加拿大、L8L 5G8
- Wharton Medical Clinic Clinical Trials (Hamilton)
-
Sarnia、Ontario、加拿大、N7T 4X3
- London Road Diagnostic Clinic and Medical Centre
-
Toronto、Ontario、加拿大、M4G 3E8
- Centricity Research Toronto
-
Toronto、Ontario、加拿大、M9V 4B4
- Albion Finch Medical Centre
-
-
Quebec
-
Lévis、Quebec、加拿大、G6W 0M5
- Centricity Research Quebec City
-
Mirabel、Quebec、加拿大、J7J 2K8
- Centricity Research Mirabel
-
Montreal、Quebec、加拿大、H1Y 3H5
- Recherche GCP Research
-
Saint-Laurent、Quebec、加拿大、H4T 1Z9
- Centricity Research Ville St. Laurent VSL
-
-
-
-
Free State
-
Bloemfontein、Free State、南非、9301
- Josha Research
-
-
Gauteng
-
Johannesburg、Gauteng、南非、2013
- Wits Bara Clinical Trial Site
-
Midrand、Gauteng、南非、1685
- Dr A Jacovides and Partners Inc
-
-
KwaZulu-Natal
-
Durban、KwaZulu-Natal、南非、4450
- Dr Pillay's Rooms
-
eMkhomazi、KwaZulu-Natal、南非、4170
- Dr T Padayachee
-
-
-
-
-
Bengaluru、印度、560054
- MS Ramaiah
-
New Delhi、印度、110001
- Lady Hardinge Medical College
-
-
Karnataka
-
Bangalore、Karnataka、印度、560092
- Life Care Hospital and Research Centre
-
-
Kerala
-
Kochi、Kerala、印度、682041
- Amrita Institute Of Medical Sciences & Research Centre
-
-
Madhya Pradesh
-
Indore、Madhya Pradesh、印度、452010
- TOTALL Diabetes Hormone Institute
-
-
Maharashtra
-
Mumbai、Maharashtra、印度、400012
- Seth GS Medical College & KEM Hospital
-
Pune、Maharashtra、印度、411021
- Chellaram Diabetes Institute
-
-
Rajasthan
-
Jaipur、Rajasthan、印度、302006
- Diabetes, Thyroid and Endocrine Centre
-
-
Tamil Nadu
-
Vellore、Tamil Nadu、印度、632004
- Christian Medical College Hospital, Vellore
-
-
Telangana
-
Hyderabad、Telangana、印度、500082
- Diabetes Research Center, Hyderabad
-
-
-
-
-
Chiba、日本、261-0004
- Tokuyama clinic_Diabetic internal medicine
-
Soka-shi, Saitama、日本、340-0015
- Soka Sugiura Internal Medicine Clinic
-
Tokyo、日本、104-0031
- Fukuwa Clinic
-
Tokyo、日本、103-0027
- Tokyo-Eki Center-building Clinic_Internal Medicine
-
Tokyo、日本、104-0031
- Fukuwa Clinic_Internal Medicine
-
-
-
-
New South Wales
-
Campbelltown、New South Wales、澳大利亚、2560
- Campbelltown Hospital
-
Macquarie Park、New South Wales、澳大利亚、2109
- Macquarie University - Clinical Trials Unit
-
St Leonards、New South Wales、澳大利亚、2065
- Royal North Shore Hospital
-
Sydney、New South Wales、澳大利亚、2148
- Western Endocrine Blacktown
-
Sydney、New South Wales、澳大利亚、2148
- Roger Chih Yu Chen
-
Wollongong、New South Wales、澳大利亚、2500
- Illawarra Diabetes Service Clinical Trials & Research Unit
-
-
Queensland
-
Birtinya、Queensland、澳大利亚、4575
- University of Sunshine Coast - Vitality Village
-
Meadowbrook、Queensland、澳大利亚、4131
- Logan Hospital
-
-
South Australia
-
Oaklands Park、South Australia、澳大利亚、5046
- Southern Adelaide Diabetes & Endocrine Services
-
-
Victoria
-
Box Hill、Victoria、澳大利亚、3128
- Eastern Clinical Research Unit Box Hill
-
Camberwell、Victoria、澳大利亚、3124
- Emeritus Research Melbourne
-
Heidelberg Heights、Victoria、澳大利亚、3081
- Austin Health, Metabolic Disorders Centre
-
Parkville、Victoria、澳大利亚、3050
- The Royal Melbourne Hospital
-
Parkville、Victoria、澳大利亚、3050
- The Royal Melbourne Hospital - Diabetes & Endocrinology Department
-
-
Western Australia
-
Fremantle、Western Australia、澳大利亚、6160
- Fremantle Hospital
-
-
-
-
California
-
Chula Vista、California、美国、91911
- Velocity Clin Res-Chula Vista
-
Fresno、California、美国、93720
- Valley Research
-
Inglewood、California、美国、90301
- 310 Clinical Research
-
La Mesa、California、美国、91942
- Velocity Clin Res San Diego
-
Lancaster、California、美国、93534
- First Valley Med Grp Lancaster
-
Lomita、California、美国、90717
- Torrance Clin Res Inst, Inc.
-
Los Alamitos、California、美国、90720
- Pacific Clinical Studies
-
Los Angeles、California、美国、90057
- Velocity Clinical Research Westlake
-
Montclair、California、美国、91763
- Catalina Research Institute, LLC
-
San Diego、California、美国、92123
- Artemis Insitute for Clin Res
-
Toluca Lake、California、美国、91602
- Med Partners, Inc.
-
Torrance、California、美国、90505
- UCLA Health Southbay Endocrine
-
Tustin、California、美国、92780
- University Clin Investigators
-
Walnut Creek、California、美国、94598
- Diablo Clinical Research, Inc.
-
-
Colorado
-
Aurora、Colorado、美国、80045
- University of Colorado Hospital
-
-
Florida
-
Clearwater、Florida、美国、33756
- Innovative Research of W Florida Inc.
-
Clearwater、Florida、美国、33756
- Innovative Research of W FL
-
Miami、Florida、美国、33183
- International Research Associates, LLC_Miami
-
-
Georgia
-
Columbus、Georgia、美国、31904
- Centricity Research
-
-
Idaho
-
Blackfoot、Idaho、美国、83221
- Elite Clinical Trials
-
-
Illinois
-
Peoria、Illinois、美国、61603
- Methodist Medical Center of Illinois
-
-
Iowa
-
Iowa City、Iowa、美国、52242
- University of Iowa
-
-
Maryland
-
Columbia、Maryland、美国、21045
- Centennial Medical Group
-
Oxon Hill、Maryland、美国、20745
- MD Medical Research
-
Rockville、Maryland、美国、20852
- Endo And Metab Cons
-
-
Missouri
-
Springfield、Missouri、美国、65807
- Clinvest Research
-
-
Montana
-
Butte、Montana、美国、59701
- Mercury Str Med Grp, PLLC
-
-
Nebraska
-
Lincoln、Nebraska、美国、68510
- Velocity Clinical Research Lincoln
-
-
Nevada
-
Las Vegas、Nevada、美国、89148
- Palm Research Center Inc-Vegas
-
Las Vegas、Nevada、美国、89109
- Excel Clinical Network
-
-
New York
-
Binghamton、New York、美国、13905
- Velocity Clinical Research Binghamton
-
-
North Carolina
-
Greensboro、North Carolina、美国、27408
- PharmQuest Life Sciences LLC
-
Wilmington、North Carolina、美国、28401
- Accellacare Wilmington
-
-
Ohio
-
Canton、Ohio、美国、44718
- Diab & Endo Assoc of Stark Co
-
Cincinnati、Ohio、美国、45242
- Velocity Clin Res_Cincinnati
-
Cincinnati、Ohio、美国、45246
- Velocity Clinical Research Springdale
-
Dayton、Ohio、美国、45439
- Providence Health Partners Ctr
-
Maumee、Ohio、美国、43537
- Advanced Med Res Maumee
-
-
Oregon
-
Grants Pass、Oregon、美国、97527
- Velocity Clin Res Grants Pass
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19114
- Tristar Clin Investigations, PC
-
Pittsburgh、Pennsylvania、美国、15243
- Preferred Primary Care Physicians Inc.
-
Uniontown、Pennsylvania、美国、15401
- Preferred Primary Care Physicians, Inc.
-
-
Texas
-
Abilene、Texas、美国、79606
- Velocity Clinical Research Abilene
-
Austin、Texas、美国、78759
- Velocity Clin Res Austin
-
Dallas、Texas、美国、75390
- UT Southwestern Med Center
-
Dallas、Texas、美国、75230
- Velocity Clinical Res-Dallas
-
Dallas、Texas、美国、75230
- Zenos Clinical research
-
Forney、Texas、美国、75126
- Care United Research, LLC
-
Houston、Texas、美国、77004
- Endocrine Associates Houston
-
Houston、Texas、美国、77043
- Biopharma Informatic_Houston
-
Irving、Texas、美国、75039
- Tekton Research
-
Lewisville、Texas、美国、75057
- Epic Clinical Research
-
Shavano Park、Texas、美国、78231
- Consano Clinical Research, LLC
-
-
Virginia
-
Burke、Virginia、美国、22015
- Burke Internal Medicine & Research
-
Newport News、Virginia、美国、23606
- TPMG Clinical Research
-
-
-
-
-
Seoul、韩国、05505
- Asan Medical Center
-
Seoul、韩国、01830
- Nowon Eulji Medical Center, Eulji University
-
Seoul、韩国、03181
- Kangbuk Samsung Hospital
-
Seoul、韩国、02841
- Korea University Anam Hospital
-
-
Gyeonggi-do
-
Seongnam-si、Gyeonggi-do、韩国、13620
- Seoul National University Bundang Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Female of non-childbearing potential, or male.
- For United States (US) only: Female of childbearing potential using highly effective non-systemic methods of contraception with low user-dependency and willingness to continue using it through-out the study or male.
- Age 18-75 years (both inclusive) at the time of signing the informed consent.
- Diagnosed with type 2 diabetes mellitus greater than or equal 180 days before screening.
- Stable daily dose(s) more than or equal 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without sodium-glucose co-transporter 2 (SGLT2) inhibitor.
- Glycated haemoglobin (HbA1c) of 7.5-10.0% (58-86 millimoles per moles (mmol/mol)) (both inclusive) as assessed by central laboratory at screening.
- Body mass index (BMI) greater than or equal 23.0 kilograms per meter square (kg/m^2).
Exclusion Criteria:
- Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
- Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Dosing scheme A (NNC0519-0130)
Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as subcutaneous (s.c.) injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
安慰剂比较:Dosing scheme A (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
实验性的:Dosing scheme B (NNC0519-0130)
Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
安慰剂比较:Dosing scheme B (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
实验性的:Dosing scheme C (NNC0519-0130)
Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
安慰剂比较:Dosing scheme C (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
实验性的:Dosing scheme D (NNC0519-0130)
Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
安慰剂比较:Dosing scheme D (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
实验性的:Dosing scheme E (NNC0519-0130)
Participants will receive NNC0519-0130 at 7 dose levels once weekly as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
安慰剂比较:Dosing scheme E (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
有源比较器:Dosing scheme F (tirzepatide)
Participants will receive tirzepatide at 6 dose levels once weekly as s.c. injection in dose escalating manner. |
Trizepatide will be administered subcutaneously. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Glycated haemoglobin (HbA1c)
大体时间:From baseline (week 0) to 12 weeks on a given maintenance dose
|
Measured as percentage point (%-point) |
From baseline (week 0) to 12 weeks on a given maintenance dose
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Glycated haemoglobin (HbA1c)
大体时间:From baseline (week 0) to end of treatment (week 36)
|
Measured as percentage point (%-point) |
From baseline (week 0) to end of treatment (week 36)
|
|
Relative change in body weight
大体时间:From baseline (week 0) to end of treatment (week 36)
|
Measured as percentage (%) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in body weight
大体时间:From baseline (week 0) to end of treatment (week 36)
|
Measured as kilograms (kg) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in fasting plasma glucose (FPG)
大体时间:From baseline (week 0) to 12 weeks on a given maintenance dose
|
Measured as millimoles per liter (mmol/L) |
From baseline (week 0) to 12 weeks on a given maintenance dose
|
|
Continuous glucose monitoring (CGM): Change in time in range (TIR) 3.9-10.0 millimoles per liter (mmol/L) (70-180 milligrams per deciliter (mg/dL))
大体时间:From baseline (week -2 to week 0) to week 22-24 and week 34-36, respectively
|
Measured as percentage point (%-point) |
From baseline (week -2 to week 0) to week 22-24 and week 34-36, respectively
|
|
Change in waist circumference
大体时间:From baseline (week 0) to end of treatment (week 36)
|
Measured as centimeter (cm) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in systolic blood pressure (SBP)
大体时间:From baseline (week 0) to end of treatment (week 36)
|
Measured as millimeters of mercury (mmHg) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high sensitivity C-Reactive Protein (hsCRP)
大体时间:From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in total cholesterol
大体时间:From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high-density lipoprotein (HDL) cholesterol
大体时间:From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in low-density lipoprotein (LDL) cholesterol
大体时间:From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in triglycerides
大体时间:From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Number of adverse events
大体时间:From baseline (week 0) to end of study (week 40)
|
Measured as number of events |
From baseline (week 0) to end of study (week 40)
|
合作者和调查者
调查人员
- 研究主任:Clinical Transparency (dept. 2834)、Novo Nordisk A/S
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- NN9541-4945
- U1111-1291-9196 (其他标识符:World Health Organization (WHO))
- jRCT2031230704 (注册表标识符:JRCT)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.